[3.2.0] Heterocyclic compounds and methods of using the same

Details [3.2.0] Heterocyclic compounds and methods of using the same [3.2.0] Heterocyclic compounds and methods of using the same

2007-10-01

2009-06-09

Anderson, Rebecca L (Department: 1626)

Organic compounds -- part of the class 532-570 series

Organic compounds

Heterocyclic carbon compounds containing a hetero ring...

C514S421000

Reexamination Certificate

active

07544814

ABSTRACT:
Compounds of Formulae I-VI and derivatives thereof having anti-cancer, anti-inflammatory, and anti-microbial properties and to compositions that include one or more of compounds and their derivatives or analogs having anti-cancer, anti-inflammatory and anti-microbial properties are disclosed. Pharmaceutical compositions comprising such compounds and methods of treating cancer, inflammatory conditions, and microbial infections with the disclosed compounds or the disclosed pharmaceutical compositions are also disclosed.

REFERENCES:
patent: 5445829 (1995-08-01), Paradissis et al.
patent: 5576012 (1996-11-01), Bauer et al.
patent: 5601845 (1997-02-01), Buxton et al.
patent: 5641515 (1997-06-01), Ramtoola
patent: 5653987 (1997-08-01), Modi et al.
patent: 5654286 (1997-08-01), Hostetler
patent: 5667809 (1997-09-01), Trevino et al.
patent: 5683676 (1997-11-01), Akehurst et al.
patent: 5688529 (1997-11-01), Lidgate et al.
patent: 5707615 (1998-01-01), Cardin et al.
patent: 5707641 (1998-01-01), Gertner et al.
patent: 5726181 (1998-03-01), Hausheer et al.
patent: 5733888 (1998-03-01), Carver et al.
patent: 5756764 (1998-05-01), Fenteany et al.
patent: 5874443 (1999-02-01), Kiely et al.
patent: 5886210 (1999-03-01), Rayle et al.
patent: 5922683 (1999-07-01), Or et al.
patent: 6133308 (2000-10-01), Soucy et al.
patent: 6147223 (2000-11-01), Fenteany et al.
patent: 6214862 (2001-04-01), Fenteany et al.
patent: 6271199 (2001-08-01), Brand et al.
patent: 6294560 (2001-09-01), Soucy et al.
patent: 6333358 (2001-12-01), Nakazato et al.
patent: 6335358 (2002-01-01), Fenteany et al.
patent: 6350759 (2002-02-01), Casara et al.
patent: 6458825 (2002-10-01), Fenteany et al.
patent: 6500825 (2002-12-01), Lan et al.
patent: 6506787 (2003-01-01), Fujishita et al.
patent: 6509331 (2003-01-01), Audia et al.
patent: 6566553 (2003-05-01), Soucy et al.
patent: 6645999 (2003-11-01), Schreiber et al.
patent: 6794516 (2004-09-01), Soucy et al.
patent: 6838477 (2005-01-01), Schreiber et al.
patent: 6849743 (2005-02-01), Soucy et al.
patent: 7144723 (2006-12-01), Fenical et al.
patent: 7176232 (2007-02-01), Fenical et al.
patent: 7176233 (2007-02-01), Fenical et al.
patent: 7179834 (2007-02-01), Fencial et al.
patent: 7183417 (2007-02-01), Corey
patent: 7276530 (2007-10-01), Potts et al.
patent: 2001/0051654 (2001-12-01), Elliott et al.
patent: 2005/0049294 (2005-03-01), Palladino et al.
patent: 2005/0203162 (2005-09-01), Xiao et al.
patent: 2006/0008852 (2006-01-01), Fenical et al.
patent: 2006/0229353 (2006-10-01), Stadler et al.
patent: 2006/0264495 (2006-11-01), Palladino et al.
patent: 2006/0287520 (2006-12-01), Danishefsky et al.
patent: 2007/0004676 (2007-01-01), Palladino et al.
patent: 2007/0155815 (2007-07-01), Fenical et al.
patent: 2007/0225350 (2007-09-01), Anderson et al.
patent: 2008/0070273 (2008-03-01), Fenical et al.
patent: 2429163 (2002-06-01), None
patent: WO 96/32105 (1996-10-01), None
patent: WO 99/09006 (1999-02-01), None
patent: WO 99/15183 (1999-04-01), None
patent: WO 00/23614 (2000-04-01), None
patent: WO 02/47610 (2002-06-01), None
patent: WO 2004/043374 (2004-05-01), None
patent: WO 2004/071382 (2004-08-01), None
patent: WO 2005/002572 (2005-01-01), None
patent: WO 2005/003137 (2005-01-01), None
patent: WO 2005/099687 (2005-10-01), None
patent: WO 2006/005551 (2006-01-01), None
patent: WO 2006/028525 (2006-03-01), None
patent: WO 2006/060609 (2006-06-01), None
patent: WO 2006/060809 (2006-06-01), None
patent: WO 2006/118973 (2006-11-01), None
patent: WO 2007/021897 (2007-02-01), None
patent: WO 2007/033039 (2007-03-01), None
Feling et al. Angew. Chem. Int. Ed. 2003, 42(3), 355-357.
Adams, Julian, “Proteasome Inhibitors as New Anticancer Drugs”,Curr. Opin. Oncol., (2002) 14:628.
Adams, et al., “Proteasome Inhibitors: A Novel Class of Potent and Effective Antitumor Agents”,Cancer Res., (1999) 59:2615.
Adams, J., “The Development of Novel Targeted Therapeutics for Treatment of Multiple Myeloma Research Roundtable”,Euro. J. Haematology, (2003) 70:263-272.
Alessandri, et al., “Mobilization of Capillary Endothelium in Vitro Induced by Effectors of Angiogenesis in Vivo”,Cancer Res., (1983) 43(4):1790-1797.
Alm, et al., “Effects of Topically Applied PGF2 and its Isopropylester on Normal and Glaucomatous Human Eyes”,Prog. Clin. Biol. Res., (1989) 312:447-58.
Beers et al., “The Merck Manual of Diagnosis and Therapy,” 17th Ed. 1999, published by Merck Research Laboratories, pp. 397-398, 948-949, 1916 and 1979-1981.
Beers, et al., “Bacterial Diseases”The Merck Research Laboratories, Whitehouse Station N.J. XP002318189 157(13): 1157-1158.
Beers, et al., “Parasitic Infections”Merck Research Laboratories, Whitehouse Station N.J. XP002318189. 1241-1252.
Bernan, et al., “Marine Microorganisms as a Source of New Natural Products”,Advances in Applied Microbiology, (1997) 43:57-90.
Bhalla, et al., “High-Dose Mitoxantrone Induces Programmed Cell Death or Apoptosis in Human Myeloid Leukemia Cells”,Blood, (1993) 82(10):3133-3140.
Bicknell, et al., “Tumour Angiogenesis”,Oxford University Press, New York (1997) pp. 5 Content.
Blum, et al., “Adriamycin: A New Anticancer Drug with Significant Clinical Activity”,Ann Intern Med, (1974) 80:249-59.
Blunt, et al., “Marine Natural Products”,Nat. Prod. Rep., (2003) 20:1-48.
Bodart, et al., “Anthrax, MEK and Cancer”,Cell Cycle, (2002) 1:10-15.
Bradley, et al., “Identification of the Cellular Receptor for Anthrax Toxin”,Nature, (2001) 414:225-9.
Bull, et al., “Search and Discovery Strategies for Biotechnology: the Paradigm Shift”,Microbiol Mol. Biol. Rev., (2000) 64:573-606.
Carey, Francis, “Organic Chemistry”, 2d ed.,McGraw Hill, Inc., New York (1992) 328-331.
Chauhan, et al., “A New Orally Active Proteasome Inhibitor Induces Apoptosis in Multiple Myeloma Cells with Mechanisms Distinct from Bortezomib”,Cancer Cell, (2005) 8:407-19.
Chauhan, et al., “A Novel Proteasome Inhibitor NPI-0052 as an Anticancer Therapy,”British Journal of Cancer, (2006) 95(8):961-965.
Cheng, et al., “Arenaric Acid, a New Pentacyclic Polyether Produced by a Marine Bacterium (Actinomycetales)”,J. Natural Products, (1999) 62:605-607.
Cheng, et al., “Luisols A and B, New Aromatic Tetraols Produced by an Estuarine Marine Bacterium of the GenusStreptomyces(Actinomycetales)”,J. Natural Products, (1999) 62:608-610.
Claverol, et al., “Mapping and Structural Dissection of Human 20 S Proteasome Using Proteomic Approaches”,Mol Cell Proteomics, (2002) 1:567-78.
Colquhoun, et al, “Rapid Characterization of Deep-Sea Actionmycetes for Biotechnology Screening Programmes”,Antonie Van Leeuwenoek, Dordrecht, (2000) 77:359-367.
Colquhoun, et al., “Novel Rhodococci and Other Mycolate Actinomycetes From the Deep Sea”,Antonie van Leeuwenhoek, (1998) 74:27-40.
Colquhoun, et al., “Taxonomy and Biotransformation Activites of Some Deep-Sea Actinomycetes”,Extremophiles, (1998) 2:269-277.
Corey et al. “The Structural Requirements for Inhibition of Proteasome Function by the Lactacystin-derived beta-lactone and Synthetic Analogs”,Tetrahedron(1999) 55(11):3305-3316.
Crane, et al., “A Novel Enantioselective Synthetic Route to Omuralide Analogues with the Potential for Species Selectivity in Proteasome Inhibition”,Organic Letters, (2001) 1395-1397.
Cragg, et al. “Chemical Diversity: A Function of Biodiversity”,Trends Pharmacol Sci, (2002) 23:404.
Crueger, et al., “Biotechnology: A Textbook of Industrial Microbiology”, 2nd.,Science Tech Publishers, (1989) Chapter 2:5-8.
Cusack, et al., “Enhanced Chemosensitivity to CPT-11 with Proteasome Inhibitor PS-341: Implications for Systemic Nuclear Factor-kB Inhibition”,Cancer Res., (2001) 61:3535-64.
Cusack, et al., NPI-0052 Enhances Tumoricidal Response to Conventional

Affiliated with

Also associated with

Rating

[3.2.0] Heterocyclic compounds and methods of using the same does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with [3.2.0] Heterocyclic compounds and methods of using the same, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and [3.2.0] Heterocyclic compounds and methods of using the same will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4103897